Search

Displaying results 5991 - 6000 of 10000 in total
  1. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  2. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  3. Drug

    Phosphonothreonine

    go.drugbank.com/drugs/DB02482
    Experimental

    Used as an identifier in the analysis of peptides, proteins, and enzymes. [PubChem]

  4. Drug

    Altropane I-123

    go.drugbank.com/drugs/DB15144
    Investigational

    Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

    Synonyms: Altropane I-123
  5. Drug

    D-Phenylalanine

    go.drugbank.com/drugs/DB02556
    Experimental

    An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]

  6. Drug

    Tasosartan

    go.drugbank.com/drugs/DB01349
    Experimental

    It is used to treat patients with essential hypertension. … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan.

    Categories: Angiotensin II receptor blockers (ARBs), plain, Agents Acting on the Renin-Angiotensin System
  7. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours. … SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C.

  8. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use. … Vanoxerine is a highly selective dopamine transporter antagonist. It was synthesized in the late 1970s and developed as a potential treatment for depression.

  9. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.

  10. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. … It is a dual agent with both immunomodulatory and antiproliferative activities.